## **DATA REPORT**

## Powder X-ray diffraction of fluorometholone, C<sub>22</sub>H<sub>29</sub>FO<sub>4</sub>

Diana Gonzalez, 1 Joseph T. Golab, 1 James A. Kaduk , 2,3,a) Amy M. Gindhart, 4 and Thomas N. Blanton 64

<sup>1</sup>Illinois Mathematics and Science Academy, 1500 Sullivan Rd., Aurora, Illinois 60506-1000, USA

(Received 29 November 2019; accepted 10 December 2019)

Commercial fluorometholone, CAS #426-13-1, crystallizes in the monoclinic space group P2<sub>1</sub> (#4) with a = 6.40648(2), b = 13.43260(5), c = 11.00060(8) Å,  $\beta = 92.8203(5)^{\circ}$ , V = 945.517(5) Å<sup>3</sup>, and Z=2. A reduced cell search in the Cambridge Structural Database yielded one previous structure determination, using single-crystal data at 292 K. In this work, the sample was ordered from the United States Pharmacopeial Convention (Lot # R032K0) and analyzed as-received. The room temperature (295 K) crystal structure was refined using synchrotron ( $\lambda = 0.412826 \text{ Å}$ ) powder diffraction data and optimized using density functional theory (DFT) techniques. Hydrogen positions were included as a part of the structure and were re-calculated during the refinement. The diffraction data were collected on beamline 11-BM at the Advanced Photon Source, Argonne National Laboratory, and the powder X-ray diffraction pattern of the compound has been submitted to ICDD® for inclusion in the Powder Diffraction FileTM. The agreement of the Rietveld-refined and DFT-optimized structures is excellent; the root-mean-square Cartesian displacement is 0.060 Å. In addition to the O-H···O hydrogen bonds observed by Park et al. (Park, Y. J., Lee, M. Y., and Cho, S. I. (1992). "Fluorometholone," J. Korean Chem. Soc. 36, 812-817), C-H···O hydrogen bonds contribute to the crystal energy. © 2020 International Centre for Diffraction Data. [doi:10.1017/S0885715619000915]

Key words: fluorometholone, Efflumidex®, X-ray diffraction, Powder Diffraction File

Fluorometholone (brand names: Efflumidex, Flucon, FML Forte, and FML) is a prescription drug classified as a synthetic glucocorticoid used to treat optical inflammation or diseases. Commercial fluorometholone, CAS #426-13-1, crystallizes in the monoclinic space group  $P2_1$  (#4) with a =6.40648(2), b = 13.43260(5), c = 11.00060(8) Å,  $\beta = 92.8203$  $(5)^{\circ}$ ,  $V = 945.517(5) \text{ Å}^3$ , and Z = 2. A reduced cell search in the Cambridge Structural Database (Groom et al., 2016) yielded one previous structure determination (Park et al., 1992), using single-crystal data at 292 K.

In this work, the sample was ordered from the United States Pharmacopeial Convention (Lot # R032K0) and analyzed as-received. The diffraction data were collected on beamline 11-BM at the Advanced Photon Source, Argonne National Laboratory. The room temperature (295 K) crystal structure was refined using synchrotron ( $\lambda = 0.412826 \text{ Å}$ ) powder diffraction data and optimized using density functional theory (DFT) techniques. Hydrogen positions were included as a part of the structure and were re-calculated during the refinement (Figure 1).

The agreement of the Rietveld-refined and DFT-optimized structures is excellent; the root-mean-square Cartesian displacement is 0.060 Å. In addition to the O-H···O hydrogen bonds observed by Park et al. (1992), C-H···O hydrogen bonds contribute to the crystal energy (Table I). The powder X-ray diffraction pattern of the compound has been submitted to ICDD® for inclusion in the Powder Diffraction File<sup>TM</sup>.

## **DEPOSITED DATA**

CIF and/or RAW data files were deposited with ICDD. You may request this data from ICDD at info@icdd.com.

## **ACKNOWLEDGEMENTS**

The use of the Advanced Photon Source at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, and Office of Basic Energy Sciences under Contract No. DE-AC02-06CH11357. This work was partially supported by the International Centre for Diffraction Data.

Groom,, C. R., Bruno,, I. J., Lightfoot, M. P., and Ward,, S. C. (2016). "The Cambridge Structural Database," Acta Crystallogr. B. 72, 171-179. Park,, Y. J., Lee,, M. Y., and Cho,, S. I. (1992). "Fluorometholone," J. Korean Chem. Soc. 36, 812-817.

<sup>&</sup>lt;sup>2</sup>Illinois Institute of Technology, 3101 S. Dearborn St., Chicago, Illinois 60616, USA

<sup>&</sup>lt;sup>3</sup>North Central College, 131 S. Loomis St., Naperville, Illinois 60540, USA

<sup>&</sup>lt;sup>4</sup>ICDD, 12 Campus Blvd., Newtown Square, Pennsylvania 19073-3273, USA

<sup>&</sup>lt;sup>a)</sup>Author to whom correspondence should be addressed. Electronic mail: kaduk@polycrystallography.com




Figure 1. Powder X-ray diffraction pattern of fluorometholone. The Rietveld-refined structure is indicated in red, and the DFT-optimized structure is indicated in blue.

TABLE I. Hydrogen bonds (CRYSTAL14) in fluorometholone.

H-bond	D–H (Å)	H···A (Å)	D···A (Å)	D–H···A (°)	Overlap (e)	$E  ext{ (kcal mol}^{-1})$
O3–H29···O1	0.980	1.784	2.753	169.1	0.050	12.2
O2-H28···O3	0.979	1.892	2.835	160.7	0.059	13.3
C22-H27···O4	1.094	2.599	3.686	172.5	0.012	a
C21-H23···O1	1.096	2.525	3.567	158.5	0.017	a
C16-H14···O4	1.091	$2.387^{b}$	2.840	103.1	0.014	a
C1-H1···O4	1.087	2.515	3.598	173.4	0.020	a

 $<sup>^{\</sup>mathrm{a}}$ Correlation between overlap population and hydrogen bond energy not yet available for C–H···O hydrogen bonds.

<sup>&</sup>lt;sup>b</sup>Intramolecular.